442 related articles for article (PubMed ID: 26017117)
1. Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
Huang Z; Huang Y; He H; Ni J
Mol Med Rep; 2015 Sep; 12(3):3916-3922. PubMed ID: 26017117
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
3. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
[TBL] [Abstract][Full Text] [Related]
4. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.
Tang Q; Yuan Q; Li H; Wang W; Xie G; Zhu K; Li D
Biochem Biophys Res Commun; 2018 Mar; 497(3):827-834. PubMed ID: 29432736
[TBL] [Abstract][Full Text] [Related]
5. Bmi1 essentially mediates podocalyxin-enhanced Cisplatin chemoresistance in oral tongue squamous cell carcinoma.
Zhou Y; Zhang L; Pan H; Wang B; Yan F; Fang X; Munnee K; Tang Z
PLoS One; 2015; 10(4):e0123208. PubMed ID: 25915207
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
7. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
8. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.
Zhou Y; Huang Z; Wu S; Zang X; Liu M; Shi J
J Exp Clin Cancer Res; 2014 Jan; 33(1):12. PubMed ID: 24468065
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway.
Liu B; Xu L; Dai EN; Tian JX; Li JM
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30442873
[TBL] [Abstract][Full Text] [Related]
10. ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway.
Li H; Shen X; Ma M; Liu W; Yang W; Wang P; Cai Z; Mi R; Lu Y; Zhuang J; Jiang Y; Song Y; Wu Y; Shen H
J Exp Clin Cancer Res; 2021 Oct; 40(1):340. PubMed ID: 34706747
[TBL] [Abstract][Full Text] [Related]
11. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
12. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
[TBL] [Abstract][Full Text] [Related]
13. miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through Twist.
Peng F; Zhang H; Du Y; Tan P
Oncol Rep; 2015 Feb; 33(2):942-50. PubMed ID: 25501015
[TBL] [Abstract][Full Text] [Related]
14. Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells.
Zhao L; Zhang W; Zhang F
Phytother Res; 2021 Jan; 35(1):278-288. PubMed ID: 32779800
[TBL] [Abstract][Full Text] [Related]
15. Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells.
Kim HJ; Lee SG; Kim YJ; Park JE; Lee KY; Yoo YH; Kim JM
Int J Oncol; 2013 Jun; 42(6):1985-92. PubMed ID: 23563171
[TBL] [Abstract][Full Text] [Related]
16. TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin.
Wu J; Liao Q; He H; Zhong D; Yin K
Mol Carcinog; 2014 Jun; 53(6):440-6. PubMed ID: 23280703
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of long noncoding RNA urothelial cancer-associated 1 enhances cisplatin chemosensitivity in tongue squamous cell carcinoma cells.
Wang J; Li L; Wu K; Ge W; Zhang Z; Gong L; Yuan D
Pharmazie; 2016 Oct; 71(10):598-602. PubMed ID: 29441929
[TBL] [Abstract][Full Text] [Related]
18. GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy.
Kim M; Jung JY; Choi S; Lee H; Morales LD; Koh JT; Kim SH; Choi YD; Choi C; Slaga TJ; Kim WJ; Kim DJ
Autophagy; 2017 Jan; 13(1):149-168. PubMed ID: 27754745
[TBL] [Abstract][Full Text] [Related]
19. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
20. TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma.
Li C; Cai J; Ge F; Wang G
Int J Mol Med; 2018 Oct; 42(4):1799-1808. PubMed ID: 30015899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
